Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Blinklab Limited ( (AU:BB1) ) has issued an update.
BlinkLab Limited has announced the addition of Cincinnati Children’s Medical Center and Seattle Children’s Research Institute as new clinical trial sites for its pivotal FDA 510(k) Autism Diagnostic Trial. These partnerships enhance BlinkLab’s clinical network to five sites in the U.S., aiming to accelerate recruitment and ensure diverse patient representation. The study is expected to complete by Q2 2026, with FDA submission anticipated in Q3 2026, potentially strengthening BlinkLab’s position in the digital healthcare industry.
More about Blinklab Limited
BlinkLab Limited is a digital healthcare company specializing in the development of AI-powered diagnostic tools. The company focuses on creating innovative solutions for healthcare diagnostics, with a particular emphasis on smartphone-based platforms.
Average Trading Volume: 253,798
Technical Sentiment Signal: Strong Buy
For a thorough assessment of BB1 stock, go to TipRanks’ Stock Analysis page.